The present invention provides for an antiviral compound and analogues thereof for treatment or prevention of Flavivirus Dengue/Zika infections. In general the antiviral compound includes Eplerenone [pregn-4-ene-7, 21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, γ-lactone, methyl ester (7α, 11α, 17α)] and its metabolites. Methods presented include treating Flavivirus infections, such as Zika virus, dengue virus, yellow fever virus and tick-borne encephalitis virus and Japanese encephalitis virus by administering the compound Eplerenone in therapeutically effective amounts and specific formulations as disclosed.

The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.

The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.

The present invention relates to pharmaceutical combinations comprising aminoacetonitrile derivatives and anticancer compounds. Further, the present invention relates to these pharmaceutical combinations for use in the treatment of cancer.

The present invention relates to pharmaceutical combinations comprising aminoacetonitrile derivatives and anticancer compounds. Further, the present invention relates to these pharmaceutical combinations for use in the treatment of cancer.

Disclosed are methods for treating cystic fibrosis characterized by a class I nonsense mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in a subject in need thereof. The method comprises administering to the subject a pharmaceutical composition comprising an effective amount of an inhibitor selected from the group consisting of a sodium glucose co-transporter (SGLT) inhibitor, a Na.sup.+/K.sup.+-ATPase inhibitor, an SGLT1/Na.sup.+/K.sup.+-ATPase dual inhibitor, and combinations thereof.

Disclosed are methods for treating cystic fibrosis characterized by a class I nonsense mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in a subject in need thereof. The method comprises administering to the subject a pharmaceutical composition comprising an effective amount of an inhibitor selected from the group consisting of a sodium glucose co-transporter (SGLT) inhibitor, a Na.sup.+/K.sup.+-ATPase inhibitor, an SGLT1/Na.sup.+/K.sup.+-ATPase dual inhibitor, and combinations thereof.

Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

Provided herein, inter alia, are methods, compositions and kits for treating cancer in a subject. The methods include administration of one or more tyrosine kinase inhibitors and triptolide or an analog thereof to the subject. The methods, compositions and kits are effective for preventing resistance and/or increasing sensitivity to tyrosine kinase inhibitors.

The present invention relates to a method of treating or preventing hair loss or excessive hair shedding in a subject by administering to a subject an oral dose of minoxidil. In particular, the present invention relates to a method of treating telogen effluvium in a subject by administering to a subject an oral dose of minoxidil.